If I could just get my wife out of the saddle and to retire I'd be playing in her IRA and buying some biotechnology to speculate for quick money without tax considerations. "There are 101 companies in the Nasdaq Biotechnology Index with less than $100 million in revenue in the trailing four quarters, according to FactSet. Combined, they had revenue of $2.5 billion. Yet their total market value is nearly $130 billion, about 52 times sales. Compare that with a bigger more established biotech like Amgen. It has a market value of slightly less than $120 billion and trades at a price/sales ratio of just six times. Remember, too, that clinical stage biotech firms earn a significant portion of revenue from research grants and milestone payments, rather than product sales. Given this, investors are paying dearly for potential drugs, or the chance of being bought out. Granted, big pharmaceuticals companies seem intent on growing by acquisition. At some point, though, the deal making music will stop. When it does, quite a few biotech investors might be left without a chair." Just thought you'd like to know the game.